Q-Line Biotech, a company in the Medical Equipment & Supplies industry, reported revenue of ₹152 crore and net profit of ₹20 crore for the September 2026 quarter.
Q-Line Biotech (NSE: QLINE-SM) closed at ₹396.80 on 20 Nov 2026. Its market capitalisation is ₹926 crore and it trades at 16.9 times earnings.
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.